Stay updated on SAGE-217 Safety in MDD Insomnia Clinical Trial
Sign up to get notified when there's something new on the SAGE-217 Safety in MDD Insomnia Clinical Trial page.

Latest updates to the SAGE-217 Safety in MDD Insomnia Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedLocations section updated to add a comprehensive list of participating sites across multiple states. The previous state-level entries were removed and the page shows Revision: v3.3.3.SummaryDifference2%

- Check27 days agoNo Change Detected
- Check42 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2; no changes to study content, locations, or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check49 days agoChange DetectedRevision label updated from Revision: v3.2.0 to Revision: v3.3.1 on the page footer; otherwise study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check56 days agoChange DetectedA funding/operating-status notice was removed from the page. This change eliminates a general operational update and does not alter the study details or eligibility.SummaryDifference0.3%

- Check70 days agoChange DetectedThe sponsor of the study changed from Sage Therapeutics to Biogen, and Biogen is now listed as the sponsor and responsible party. Related sections such as the official title and sponsor information reflect Biogen’s involvement.SummaryDifference0.4%

- Check99 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference2%

Stay in the know with updates to SAGE-217 Safety in MDD Insomnia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAGE-217 Safety in MDD Insomnia Clinical Trial page.